Efficacy and safety of PD-1/PD-L1 and CTLA-4 immune checkpoint inhibitors in colorectal cancer: a meta-analysis

被引：14

作者：

Jin, Chunhui ^{[1
]}

Zhu, Xiaodan ^{[1
]}

Huang, Xiaona ^{[1
]}

Gong, Tingjie ^{[1
]}

Wei, Zhipeng ^{[1
]}

You, Jianliang ^{[1
]}

机构：

[1] Nanjing Univ Chinese Med, Wuxi Hosp, Dept Oncol, Wuxi 214001, Jiangsu, Peoples R China

来源：

JOURNAL OF COMPARATIVE EFFECTIVENESS RESEARCH | 2021年 / 11卷 / 03期

关键词：

clinical trials; CTLA-4 colorectal cancer; immune checkpoint blockade; meta-analysis; PD-1; PD-L1; BLOCKADE; INSTABILITY; NIVOLUMAB; TREMELIMUMAB; MULTICENTER; TUMORS;

D O I：

10.2217/cer-2021-0134

中图分类号：

R19 [保健组织与事业（卫生事业管理）];

学科分类号：

摘要：

Aims: To evaluate the efficacy and safety of PD-1/PD-L1 and/or CTLA-4 inhibitors in the treatment of colorectal cancer (CRC) by meta-analysis. Methods: Electronic databases were searched. Eligible studies included investigations of efficacy and safety of anti-PD-1/PD-L1 or anti-CTLA-4 agents in patients with CRC. Corresponding indicators were calculated. Results: A total of 15 articles were included. The pooled objective response rate, overall survival rate, progression-free survival rate and adverse event rate were 33, 56, 46 and 59%, respectively. The objective response rates for CRC with deficient mismatch repair and CRC with proficient mismatch repair were 43 and 3%, respectively, in patients treated with PD-1 inhibitors. Conclusion: The authors' study indicates that PD-1/PD-L1 inhibitors manifest promising clinical responses in the treatment of CRC with deficient mismatch repair with acceptable treatment-related adverse events.

引用

页码：203 / 212

页数：10

共 47 条

[1] Pembrolizumab in Microsatellite-Instability-High Advanced Colorectal Cancer [J].

Andre, T. ;

Shiu, K-K ;

Kim, T. W. ;

Jensen, B., V ;

Jensen, L. H. ;

Punt, C. ;

Smith, D. ;

Garcia-Carbonero, R. ;

Benavides, M. ;

Gibbs, P. ;

de la Fouchardiere, C. ;

Rivera, F. ;

Elez, E. ;

Bendell, J. ;

Le, D. T. ;

Yoshino, T. ;

Van Cutsem, E. ;

Yang, P. ;

Farooqui, M. Z. H. ;

Marinello, P. ;

Diaz, L. A., Jr. .

NEW ENGLAND JOURNAL OF MEDICINE, 2020, 383 (23) :2207-2218

[2] The role of PD-1/PD-L1 axis and macrophage in the progression and treatment of cancer [J].

Cai, Jiajing ;

Qi, Qi ;

Qian, Xuemeng ;

Han, Jia ;

Zhu, Xinfang ;

Zhang, Qi ;

Xia, Rong .

JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, 2019, 145 (06) :1377-1385

[3] Treatment in advanced colorectal cancer: what, when and how? [J].

Chau, I. ;

Cunningham, D. .

BRITISH JOURNAL OF CANCER, 2009, 100 (11) :1704-1719

[4] Effect of Combined Immune Checkpoint Inhibition vs Best Supportive Care Alone in Patients With Advanced Colorectal Cancer The Canadian Cancer Trials Group CO.26 Study [J].

Chen, Eric X. ;

Jonker, Derek J. ;

Loree, Jonathan M. ;

Kennecke, Hagen F. ;

Berry, Scott R. ;

Couture, Felix ;

Ahmad, Chaudhary E. ;

Goffin, John R. ;

Kavan, Petr ;

Harb, Mohammed ;

Colwell, Bruce ;

Samimi, Setareh ;

Samson, Benoit ;

Abbas, Tahir ;

Aucoin, Nathalie ;

Aubin, Francine ;

Koski, Sheryl L. ;

Wei, Alice C. ;

Magoski, Nadine M. ;

Tu, Dongsheng ;

O'Callaghan, Chris J. .

JAMA ONCOLOGY, 2020, 6 (06) :831-838

[5] Phase II Study of the Anti-Cytotoxic T-Lymphocyte-Associated Antigen 4 Monoclonal Antibody, Tremelimumab, in Patients With Refractory Metastatic Colorectal Cancer [J].

Chung, Ki Y. ;

Gore, Ira ;

Fong, Lawrence ;

Venook, Alan ;

Beck, Stephen B. ;

Dorazio, Prudence ;

Criscitiello, Peggy J. ;

Healey, Diane I. ;

Huang, Bo ;

Gomez-Navarro, Jesus ;

Saltz, Leonard B. .

JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (21) :3485-3490

[6] RECIST and iRECIST criteria for the evaluation of nivolumab plus ipilimumab in patients with microsatellite instability-high/mismatch repair-deficient metastatic colorectal cancer: the GERCOR NIPICOL phase II study [J].

Cohen, Romain ;

Bennouna, Jaafar ;

Meurisse, Aurelia ;

Tournigand, Christophe ;

De La Fouchardiere, Christelle ;

Tougeron, David ;

Borg, Christophe ;

Mazard, Thibault ;

Chibaudel, Benoist ;

Garcia-Larnicol, Marie-Line ;

Svrcek, Magali ;

Vernerey, Dewi ;

Menu, Yves ;

Andre, Thierry .

JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2020, 8 (02)

[7] Promising New Agents for Colorectal Cancer [J].

Das, Satya ;

Ciombor, Kristen K. ;

Haraldsdottir, Sigurdis ;

Goldberg, Richard M. .

CURRENT TREATMENT OPTIONS IN ONCOLOGY, 2018, 19 (06)

[8] New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1) [J].

Eisenhauer, E. A. ;

Therasse, P. ;

Bogaerts, J. ;

Schwartz, L. H. ;

Sargent, D. ;

Ford, R. ;

Dancey, J. ;

Arbuck, S. ;

Gwyther, S. ;

Mooney, M. ;

Rubinstein, L. ;

Shankar, L. ;

Dodd, L. ;

Kaplan, R. ;

Lacombe, D. ;

Verweij, J. .

EUROPEAN JOURNAL OF CANCER, 2009, 45 (02) :228-247

[9] Results and challenges of immune checkpoint inhibitors in colorectal cancer [J].

Emambux, Sheik ;

Tachon, Gaelle ;

Junca, Audelaure ;

Tougeron, David .

EXPERT OPINION ON BIOLOGICAL THERAPY, 2018, 18 (05) :561-573

[10] Immunotherapy in colorectal cancer: rationale, challenges and potential [J].

Ganesh, Karuna ;

Stadler, Zsofia K. ;

Cercek, Andrea ;

Mendelsohn, Robin B. ;

Shia, Jinru ;

Segal, Neil H. ;

Diaz, Luis A., Jr. .

NATURE REVIEWS GASTROENTEROLOGY & HEPATOLOGY, 2019, 16 (06) :361-375

← 1 2 3 4 5 →